Literature DB >> 8585935

Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy.

S G Elner1, V M Elner, G J Jaffe, A Stuart, S L Kunkel, R M Strieter.   

Abstract

We determined whether interleukin-8, monocyte chemotactic protein-1, and macrophage-colony stimulating factor are present in the vitreous of patients with proliferative diabetic retinopathy (PDR) or proliferative vitreoretinopathy (PVR). The levels of these cytokines were measured by specific enzyme-linked immunoassays in vitreous from 30 patients with PDR, 13 patients with PVR, and 26 control individuals, including 10 cadaver eyes and 16 patients with idiopathic macular holes, idiopathic macular puckers, vitreous hemorrhages, or uncomplicated retinal detachments. Detectable levels of interleukin-8 were found in 90% of vitreous samples of patients with PDR, 85% with PVR, and 58% of control samples. IL-8 was significantly increased in PDR (mean +/- SEM; 25.0 +/- 5.3 ng/ml; p = 0.01), but not in PVR (11.9 +/- 3.9 ng/ml; p = 0.50) compared to control human vitreous (8.5 +/- 2.5 2.5 ng/ml). MCP-1 was detected in 90% of vitreous samples of patients with PDR, 92% with PVR, and 81% of control samples. MCP-1 was significantly increased in PDR (6.2 +/- 0.9 ng/ml, p = 0.001) and PVR (7.7 +/- 2.5 ng/ml, p = 0.001) over the levels in control vitreous (1.2 +/- 0.2 ng/ml). M-CSF was detected in 94% of vitreous samples of patients with PDR, 88% with PVR, and 92% from control vitreous. M-CSF was significantly elevated in PDR (32.3 +/- 8.3 ng/ml, p = 0.03), but not in PVR (23.6 +/- 12.8 ng/ml, p = 0.4) compared to control (10.7 +/- 3.5 ng/ml). Our results suggest that IL-8, MCP-1, and M-CSF participate in the pathogenesis of PDR and PVR.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8585935     DOI: 10.3109/02713689508998529

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  76 in total

1.  Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy.

Authors:  I A El-Ghrably; H S Dua; G M Orr; D Fischer; P J Tighe
Journal:  Br J Ophthalmol       Date:  2001-04       Impact factor: 4.638

2.  Macrophage migration inhibitory factor levels in the vitreous of patients with proliferative diabetic retinopathy.

Authors:  Y Mitamura; S Takeuchi; A Matsuda; Y Tagawa; Y Mizue; J Nishihira
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

3.  Retinal detachment after posterior segment intraocular foreign body injuries.

Authors:  A M El-Asrar; S A Al-Amro; N M Khan; D Kangave
Journal:  Int Ophthalmol       Date:  1998       Impact factor: 2.031

4.  Inhibitory effect of certain neuropeptides on the proliferation of human retinal pigment epithelial cells.

Authors:  J Troger; S Sellemond; G Kieselbach; M Kralinger; E Schmid; B Teuchner; Q A Nguyen; E Schretter-Irschick; W Göttinger
Journal:  Br J Ophthalmol       Date:  2003-11       Impact factor: 4.638

Review 5.  Diabetic periodontitis: a model for activated innate immunity and impaired resolution of inflammation.

Authors:  Hamdy Nassar; Alpdogan Kantarci; Thomas E van Dyke
Journal:  Periodontol 2000       Date:  2007       Impact factor: 7.589

6.  The kinetics of VEGF and MCP-1 in the second vitrectomy cases with proliferative diabetic retinopathy.

Authors:  Y Sassa; S Yoshida; K Ishikawa; R Asato; T Ishibashi; T Kono
Journal:  Eye (Lond)       Date:  2016-02-26       Impact factor: 3.775

7.  Feasibility study of chitosan as intravitreous tamponade material.

Authors:  Hong Yang; Rong Wang; Qisheng Gu; Xiaonong Zhang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-04-23       Impact factor: 3.117

8.  Alterations in the intraocular cytokine milieu after intravitreal bevacizumab.

Authors:  Farzin Forooghian; Peter J Kertes; Kenneth T Eng; Elvira Agrón; Emily Y Chew
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-12-10       Impact factor: 4.799

9.  Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease.

Authors:  Steven Pennock; David Kim; Shizuo Mukai; Matthew Kuhnle; Dal W Chun; Joanne Matsubara; Jing Cui; Patrick Ma; David Maberley; Arif Samad; Robert J Van Geest; Sarit L Oberstein; Reinier O Schlingemann; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2013-04-09       Impact factor: 4.307

10.  Cytotoxic effect of interleukin-8 in retinal ganglion cells and its possible mechanisms.

Authors:  Jing-Jing Wang; Walana Williams; Bing Wang; Jing Wei; Xia Lu; Jya-Wei Cheng; John R Gordon; Jing-Min Li; Fang Li
Journal:  Int J Ophthalmol       Date:  2018-08-18       Impact factor: 1.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.